FluoroDeoxyGlucose Positron Emission Tomography (FDG- PET) is an important and effective modality used for diagnosing Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI). In this paper, we develop a novel method by using single modality (FDG- PET) but multi-level features, which consider...
导语:利用颅脑18F-FDG PET,预测Alzheimer病的深度学习算法的敏感性和特异性分别为82%、100%。 来源:梅斯医学 本研究旨在利用颅脑氟18(18F)氟脱氧葡萄糖(FDG)PET数据建立并验证深度学习算法来预测Alzheimer病(AD)、轻度认知障碍或健康志愿者的明确诊断,并...
Karl HerholzInternational Psychogeriatrics
This suggests that FDG-PET is also a better means for determining the effectiveness of Alzheimer’s therapies, as well as tracking patients’ disease advancement, in both clinical and research settings. Results of this study are detailed in the August issue of theJournal of Alzheimer’s Disease....
Unlabelled:The normative reference sample is crucial for the diagnosis of Alzheimer's disease (AD) with automated (18)F-FDG PET analysis. We tested whether an (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals ("normals," or NLs) would improve diagnosis of AD and...
doi:10.1002/alz.042101Fedor LevinDaniel FerreiraCatharina LangeMartin DyrbaEric WestmanRalph BuchertStefan J. TeipelMichel J. GrotheJohn Wiley & Sons, LtdAlzheimer's & Dementia
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease (PET) and amyloid-beta pathologyusing Pittsburgh Compound-B ([11C]PIB)-PET in the evaluation of patients with Alzheimer’s disease (AD) and mild ... Yi,Li,Juha,... - 《Europe...
摘要: Background Fluorodeoxyglucose (FDG) positron emission tomography (PET) is useful to predict Alzheimer's disease (AD) conversion in patients with mild cognitive impairment (MCI). However, few studies... DOI: 10.1007/s40291-018-0334-z 年份: 2018 收藏...
F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias doi:10.2967/jnumed.114.143347Journal of Nuclear MedicineO'Brien, John T.Firbank, Michael J.Davison, ChristopherBarnett, NickyBamford, ClaireDonaldson, CamOlsen, KirstyHerholz, KarlWilliams, ...
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease where biomarkers for disease based on pathophysiology may be able to provide objective measures for disease diagnosis and staging. Neuroimaging scans acquired from MRI and metabolism im